share_log

Cosmos Health Enters Into A Material Definitive Agreement With Cana Laboratories Pursuant To The Binding Letter Of Intent; The Next Phase Is The Execution Of A Stock Purchase Agreement To Be Concluded No Later Than March 31, 2023

Cosmos Health Enters Into A Material Definitive Agreement With Cana Laboratories Pursuant To The Binding Letter Of Intent; The Next Phase Is The Execution Of A Stock Purchase Agreement To Be Concluded No Later Than March 31, 2023

Cosmos Health 根据具有约束力的意向书与 Cana Laboratories 签订了重要的最终协议;下一阶段是执行不迟于 2023 年 3 月 31 日签订的股票购买协议
Benzinga ·  2023/03/07 09:18
Cosmos Health Inc. ("Cosmos Health" or "the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has entered into a material definitive agreement with Pharmaceutical Laboratories CANA S.A., ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.
拥有营养品专有产品线和药品、品牌仿制药、非处方药和医疗器械分销商的全球医疗保健集团Cosmos Health Inc.(“Cosmos Health” 或 “公司”)(纳斯达克股票代码:COSM)今天宣布,它已与生产、销售、分销和销售研究过的原创品牌产品的希腊制药公司CANA Laboratories S.A.(“Cana”)签订了实质性的最终协议由全球领先的制药和医疗保健公司开发。
This material definitive agreement is pursuant to the Binding Letter of Intent dated July 19, 2022, and amended on January 10, 2023, which was entered into by Cosmos Health, applicable Cana entities, and...
该重要的最终协议基于2022年7月19日具有约束力的意向书...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发